PLIN5は,小島β細胞におけるPGC-1α/Drp1シグナル伝達を通じて脂質代謝を調節する
Zhenyu Sun1, Jiahao Zhao1, Siwen Fan1
1Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu Province, China.
Endocrine
|August 30, 2025
まとめ
ペリリピン5 (PLIN5) は,脂質代謝とミトコンドリア機能を調節することによって,糖尿病による損傷から臓のβ細胞を保護する. 減少したPLIN5は機能不全を悪化させ,増加したPLIN5はインスリン分泌と細胞の健康を改善します.
科学分野:
- 細胞生物学
- 代謝 疾患
- 内分泌学
背景:
- 糖尿病は臓のベータ細胞の機能障害を引き起こし,インスリン分泌を阻害する.
- 脂質代謝の調節不全とミトコンドリア機能障害は,糖尿病におけるベータ細胞不全の主要な要因である.
- ペリリピン5 (PLIN5) は脂質滴の調節とミトコンドリア動力学に関与しています.
研究 の 目的:
- 糖尿病患者における臓ベータ細胞機能障害におけるPLIN5の保護作用を調査する.
- ベータ細胞における脂質代謝とミトコンドリア動態に対するPLIN5の影響を明らかにする.
- 高グルコース環境におけるPLIN5の機能の基礎となる分子メカニズムを探求する.
主な方法:
- db/dbの糖尿病マウスとINS-1の臓ベータ細胞系を使用した.
- 高血糖状態でのインスリン分泌,脂質蓄積,アポトーシスの評価
- ウエスタン・ブロッティング,qPCR,免疫光検査,レンチウイルス感染を用いて分子メカニズムを調べた.
主要な成果:
- PLIN5の発現は糖尿病において低下し,臓の脂質蓄積と相関する.
- INS-1細胞におけるPLIN5ノックダウンにより,APOPTOSISが増加し,インスリン分泌が低下し,PGC-1αとDrp1のレベルが変化することでミトコンドリア機能が低下した.
- ヒトゲノムによる損傷からベータ細胞を保護し,インスリン分泌とミトコンドリアの健康を回復した.
結論:
- PLIN5は,高血糖にさらされた臓のベータ細胞における脂質の蓄積を調節する上で重要な役割を果たします.
- PLIN5はPGC-1αとDrp1を調節し,それによってミトコンドリアの動態とベータ細胞の機能に影響を与えます.
- 糖尿病のベータ細胞機能障害に対する治療戦略としてPLIN5をターゲットにすることが可能である.
関連する概念動画
Cell Specific Gene Expression
13.9K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416


